Clinical Trials Logo

High-risk Soft Tissue Sarcoma clinical trials

View clinical trials related to High-risk Soft Tissue Sarcoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT01898663 Active, not recruiting - Clinical trials for High-risk Soft Tissue Sarcoma

DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With High-risk Soft Tissue Sarcoma

Start date: June 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this Phase Ⅰ/Ⅱ study is to evaluate the safety and efficacy of dendritic cells (DCs) vaccine combined with cytokine-induced killer (CIK) cells in patients with high-risk soft tissue sarcoma. Experimental recombinant adenovirus-transfected DCs, which engineered to express MUC1 and Survivin are used for DCs-based immunotherapy. Based on the results of our previously performed preclinical study with DCs vaccine combined with CIK cells, the investigators plan to perform the clinical trial.